Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $24.92, for a total value of $299,040.00. Following the sale, the chief executive officer now directly owns 1,063,525 shares of the company’s stock, valued at approximately $26,503,043. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.66, for a total value of $259,920.00.
• On Tuesday, May 28th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total transaction of $278,160.00.

Enliven Therapeutics Stock Up 1.0 %

Shares of NASDAQ:ELVN opened at $26.38 on Thursday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -13.67 and a beta of 1.11. The company has a 50 day moving average of $22.80 and a two-hundred day moving average of $19.45. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

Several large investors have recently modified their holdings of ELVN. AJOVista LLC acquired a new position in shares of Enliven Therapeutics in the fourth quarter worth about $28,000. China Universal Asset Management Co. Ltd. purchased a new stake in Enliven Therapeutics during the 4th quarter worth approximately $66,000. EntryPoint Capital LLC purchased a new stake in Enliven Therapeutics during the 1st quarter worth approximately $167,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Enliven Therapeutics by 17.8% during the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after buying an additional 2,041 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Mizuho assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, Robert W. Baird assumed coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.